MOUNTAIN VIEW, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software and strategic services for optimizing clinical drug development, today announced that Andreas Krause, Ph.D., senior biostatistician, Pharsight Drug Development Consulting Services, will speak to members of the pharmaceutical and biotechnology industries attending the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting, to be held at the San Antonio Convention Center in San Antonio, Texas, October 29-November 2, 2006.
Dr. Krause will speak on the value of structured approaches to graphing clinical data as a critical tool for data exploration, covariate selection, model qualification and presentation of modeling results. Dr. Krause will join industry panelists in a session entitled “A Picture is Worth A Thousand Tables: Graphical Display of PK/PD Data.” The session will offer perspectives on effective and efficient ways to represent the vast amount of data that arises from a drug development program, and will include discussion of data exploration methods and practical examples. Additional information can be found at http://www.aapspharmaceutica.com .
“Effective visual communication of drug program data is critically important for improving the quality of drug development decisions and for developing confidence in modeling and simulation results,” said Shawn O’Connor, Pharsight president, CEO and chairman. “Pharsight is pleased to participate at the AAPS Annual Meeting, which serves as a leading global forum for pharmaceutical scientists to exchange information and best practices that contribute to the development of safe and effective new therapies.”
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company’s goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight’s approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com .
Registered Trademarks and Trademarks
Pharsight(R) is a registered trademark of Pharsight Corporation.
Pharsight Corporation
CONTACT: investors, Douglas Sherk, or Jennifer Beugelmans, both of EVCGroup, +1-415-896-6820, or media, Jen Saunders of EVC Group,+1-646-277-8720, all for Pharsight Corporation
